Financiere de Tubize SAFinanciere de Tubize SA - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The report of Financiere de Tubize SA leverages information from across the internet and also from available filings by Financiere de Tubize SA. The analysis of Financiere de Tubize SA is prepared by All Street Sevva using proprietary Cognitive Robots. The Sustainability rating for Financiere de Tubize SA represents the company's transparency towards the United Nations SDGs.

Financiere de Tubize SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 2.3, social score of 3.0 and governance score of 5.0.

SDG Transparency Score for Financiere de Tubize SA 

3.4

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Financiere de Tubize SA 
2.3

Environmental

3.0

Social

5.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1617VistaGen Therapeutics Inc
3.5
Medium
1617Yumanity Therapeutics Inc
3.5
Medium
1659Financiere de Tubize SA
3.4
Medium
1659Acceleron Pharma Inc
3.4
Medium
1659Annexin Pharmaceuticals AB (publ)
3.4
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Financiere de Tubize SA have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Financiere de Tubize SA report the average age of the workforce?

LockedSign up for free to unlock

Does Financiere de Tubize SA reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose cybersecurity risks?

LockedSign up for free to unlock

Does Financiere de Tubize SA offer flexible work?

LockedSign up for free to unlock

Does Financiere de Tubize SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Financiere de Tubize SA conduct supply chain audits?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Financiere de Tubize SA conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose water use targets?

LockedSign up for free to unlock

Does Financiere de Tubize SA have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Financiere de Tubize SA have a product recall in the last two years?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose incidents of discrimination?

LockedSign up for free to unlock

Does Financiere de Tubize SA allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Financiere de Tubize SA issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose parental leave metrics?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Financiere de Tubize SA support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Financiere de Tubize SA reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Financiere de Tubize SA involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose its waste policy?

LockedSign up for free to unlock

Does Financiere de Tubize SA report according to TCFD requirements?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose energy use targets?

LockedSign up for free to unlock

Does Financiere de Tubize SA disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Financiere de Tubize SA have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Financiere de Tubize SA
These potential risks are based on the size, segment and geographies of the company.

Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.

Sorry!

Failed to process!